There are also plenty of other ways to develop a company's scientific and selling skills: research agreements, licensing arrangements and marketing alliances between drug companies, biotechnology firms and other bodies are all less traumatic than forcing two different corporate cultures into one bed.

ECONOMIST: Drug mergers are all the rage; but few make much sense

The concept of flying around as a virtual Tony Stark has great potential, and there was plenty of time between Iron Man 2 and 3 to at least try to develop a solid game.

FORBES: Iron Man 3 Soars Past $680 Million In Box Office With Only Mobile Game Tie-In

If Doximity is to scale, it may need to pick a bigger target market or develop new products for which its doctor-members are willing to pay plenty.

FORBES: Doximity Benefits From Consumer Internet Faceplant

And it has had plenty of opportunity to interact with Genzyme: The two companies formed a joint venture to develop Aldurazyme, BioMarin's first approved drug.

FORBES: BioMarin Follows Genzyme's Playbook